CUYAHOGA FALLS, Ohio–(BUSINESS WIRE)–Americhem, a global designer and manufacturer of custom polymer solutions, today announced the acquisition of Noble Biomaterials, an advanced materials company that specializes in antimicrobial and conductivity solutions for soft surface applications. The acquisition adds Noble Biomaterials’ differentiated technologies and deep specialization to Americhem’s broader global platform, strengthening Americhem’s ability to support customers from concept through
Month: October 2026
VANCOUVER, British Columbia–(BUSINESS WIRE)–Spanish Mountain Gold Ltd. (the “Company” or “Spanish Mountain Gold”) (TSXV: SPA; FSE: S3Y; OTCQB: SPAUF) is pleased to announce that it has signed a Facilities Study Agreement (Facilities Study) with BC Hydro and Power Authority (“BC Hydro”), the provincial Crown corporation responsible for generating, purchasing, transmitting, and distributing electricity in British Columbia, for the interconnection of the Spanish Mountain Gold project (the “Projec
LONDON–(BUSINESS WIRE)– FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari
TORONTO, Oct. 27, 2026 (GLOBE NEWSWIRE) — Flow Capital Corp. (“Flow Capital” or the “Company”) (CSE: FW), a leading provider of flexible growth capital and alternative debt solutions for high-growth companies, is pleased to announce that its common shares will begin trading on the Canadian Securities Exchange (the “CSE”) under the new ticker symbol “FLOW”, effective at market open on October 29, 2026.
The new trading symbol replaces the Company’s current symbol, “FW,” and more closely aligns its public market identity with the Flow Capital brand.
No action is required by the Company’s shareholders in connection with this ticker symbol change. The CUSIP number for the Company’s common shares remains unchanged, and no steps need to be taken with respect to previously issued share certificates, as these are not affected by the symbol change.
About Flow Capital
Flow Capital Corp. is a publicly listed provider of flexible growth capital, alternative debt solutions, and small equity investments for high-growth companies. Since its inception in 2018, the Company has provided financing to businesses in the US, the UK, and Canada, helping them achieve accelerated growth without the dilutive impact of equity financing or the complexities of traditional bank loans. Flow Capital focuses on revenue-generating, VC-backed, and founder-owned companies seeking $1 to $15 million in capital to drive their continued expansion.
High-growth companies seeking covenant-light, founder-friendly growth capital are invited to apply for funding directly at www.flowcap.com.
For further information, please contact:
Flow Capital Corp.
Matthew Gan
Chief Financial Officer
matthew@flowcap.com
Forward-Looking Information and Statements
Certain statements herein may be “forward-looking” statements that involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Flow or the industry to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether such results will be achieved. A number of factors could cause actual results to vary significantly from the results discussed in the forward-looking statements. These forward-looking statements reflect current assumptions and expectations regarding future events and operating performance and are made as of the date hereof and Flow assumes no obligation, except as required by law, to update any forward-looking statements to reflect new events or circumstances.
Durable Complete Response Achieved with Single Administration of Iopofosine I 131
Provides Additional Clinical Support for the Differentiated Mechanism of Action of Iopofosine I 131 and its Potential Utility Across a Range of B-cell Malignancies
FLORHAM PARK, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today reported results from a case study highlighting a durable complete response in a heavily pretreated patient with diffuse large B-cell lymphoma (DLBCL) treated with iopofosine I 131.
The case study describes a 53-year-old woman with high-grade, double-hit DLBCL who had received four prior lines of therapy. This case demonstrates that a single administration of iopofosine I 131 produced a durable complete response lasting more than eight years in a patient with aggressive, relapsed DLBCL following multiple prior therapies and stem cell transplantation. The Company plans to submit these findings for journal publication or presentation at a medical meeting.
“This case study and results from iopofosine I 131 treatment of aggressive hematologic cancers along with the positive data generated to date in Waldenström macroglobulinemia further validate the PDC platform’s ability to selectively target malignant cells,” said James Caruso, president and chief executive officer of Cellectar. “Importantly, we are now advancing our confirmatory Phase 3 study in WM and expect to initiate patient dosing in the first quarter of 2027, with plans remaining on target to submit an accelerated approval application to the U.S. Food and Drug Administration in the first half of 2027.”
The case study is particularly noteworthy because it aligns with the compelling efficacy and durability being observed in Cellectar’s Phase 2b CLOVER WaM study in relapsed/refractory Waldenström macroglobulinemia (r/r WM), where iopofosine has generated durable responses in heavily pretreated patients, including patients refractory to prior therapies.
“While this case represents a single patient experience, we believe the durability and depth of response observed underscore the broader potential of iopofosine I 131 across B-cell malignancies,” said Jarrod Longcor, chief operating officer of Cellectar Biosciences. “These findings reinforce the compelling clinical activity observed in our Phase 2b CLOVER WaM study, in which iopofosine I 131 delivered meaningful, durable responses in heavily pretreated patients with relapsed or refractory Waldenström macroglobulinemia, including those that were refractory to Bruton’s Tyrosine Kinase inhibitors.”
Key highlights from the case study:
Treatment and Response
- Received a single dose of iopofosine I 131 (57.5 mCi) on March 20, 2018.
- Reached a response (partial response or better) by Day 48 and achieved a complete response (CR) by Day 85 following treatment, confirmed by both site investigators and sponsor assessment.
- The target lesion shrank from 825 mm³ at baseline to complete resolution (0 mm³) by Day 85.
Durability
- As of May 2026, more than eight years after a single infusion, the patient:
- Has experienced no disease progression
- Has required no additional anticancer therapy
- Duration of response, progression-free survival, and time to next treatment remain ongoing and unreached at more than eight years.
Safety
- The patient experienced expected hematologic toxicities, including anemia, lymphopenia, thrombocytopenia, and neutropenia, all of which resolved.
About Iopofosine I 131
Iopofosine I 131 is a novel phospholipid drug conjugate (PDC) designed to provide targeted delivery of iodine-131 directly to cancer cells. Leveraging the Company’s proprietary PDC platform, iopofosine selectively accumulates in malignant cells, delivering cytotoxic radiation while limiting exposure to healthy tissues. Iopofosine I 131 has been tested in Phase 2b trials as a treatment for relapsed or refractory Waldenström Macroglobulinemia (WM), in relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) lymphoma. Iopofosine I 131 has also been tested in the CLOVER-2 Phase 1b study evaluating iopofosine I 131 in pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has granted iopofosine I 131 Breakthrough, six Orphan Drug, four Rare Pediatric Drug and two Fast Track Designations for various cancer indications, and the EMA has granted iopofosine I 131 PRIority MEdicines (PRIME) designation.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.
The company’s product pipeline includes iopofosine I 131, which is a PDC designed to provide targeted delivery of iodine-131 (radioisotope). Iopofosine I 131 has been tested in Phase 2b trials as a treatment for relapsed or refractory Waldenström Macroglobulinemia (WM), in relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) lymphoma. The CLOVER-2 Phase 1b study is evaluating iopofosine I 131 in pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has granted iopofosine I 131 Breakthrough, six Orphan Drug, four Rare Pediatric Drug and two Fast Track Designations for various cancer indications, and the EMA has granted iopofosine I 131 PRIority MEdicines (PRIME) designation.
Cellectar is also developing CLR 121125 (CLR 125), an iodine-125 Auger-emitting program targeted for solid tumors, such as triple negative breast (TNBC), lung, and colorectal cancer, and is currently being evaluated in a Phase 1b study for TNBC, which will determine the recommended dose for the subsequent Phase 2 trial. CLR 125 has been well tolerated in vivo and has demonstrated strong preclinical data showing reduction or inhibition of solid tumor growth.
In addition to these assets, the Cellectar team is developing CLR 121225 (CLR 225), an actinium-225 based program targeting solid tumors in indications with significant unmet need, such as pancreatic cancer, as well as proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.
For more information, please visit https://www.cellectar.com/or join the conversation by liking and following us on the company’s social media channels: X, LinkedIn, and Facebook.
Forward Looking Statements
This news release contains forward-looking statements. You can identify these statements by our use of words such as “may,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,” “continue,” “plans,” or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the FDA and EMA regulatory pathways, ability to execute strategic alternatives, identify suitable collaborators, partners, licensees or purchasers for our product candidates and, if we are able to do so, to enter into binding agreements with regard to any of the foregoing, or to raise additional capital to support our operations, or our ability to fund our operations if we are unsuccessful with any of the foregoing. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2025, and our Form 10-Q for the quarterly period ending June 30, 2026. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.
INVESTORS:
Anne Marie Fields
Precision AQ
212-362-1200
annemarie.fields@precisionaq.com
VANCOUVER, British Columbia, Oct. 27, 2026 (GLOBE NEWSWIRE) — RecycLiCo Battery Materials Inc. (“RecycLiCo”) (TSX.V: AMY | OTCQB: AMYZF | FSE: ID4), a critical mineral refining and lithium-ion battery upcycling company, and Alaska Energy Metals Corp. (“AEMC”) (TSX.V: AEMC | OTCQB: AKEMF | FRA: V7F) are pleased to announce the commencement of testing of metal concentrate samples derived from drill core from the 2023-2024 exploration campaigns at the polymetallic Eureka deposit, located at AEMC’s Nikolai Nickel Project in Alaska. The work is being done at RecycLiCo’s laboratory in Delta, BC, in accordance with a protocol prepared by RecycLiCo and approved by AEMC. Testing is in furtherance of the previously announced memorandum of understanding (“MOU”) between AEMC and RecycLiCo’s U.S. subsidiary to assess the ways in which RecycLiCo’s hydrometallurgical processing technology could be used in refining the output from the Eureka deposit, which contains seven U.S. Government-designated Critical Minerals, including nickel, cobalt, copper, chromium, platinum, palladium, and gold (along with the non-critical mainstay metal iron). Recently reported locked cycle flotation results have proven strong recoveries of metals reporting to a bulk nickel-copper concentrate. AEMC is exploring multiple avenues for hydrometallurgical testing to determine the optimum extraction technique to achieve the highest value from downstream processing of the bulk concentrate.
“We are pleased to be assisting AEMC with this important phase of their Nikolai Project. We expect to demonstrate the benefits of using our hydrometallurgical solutions in the recovery of high value materials essential to the establishment of a wholly domestic critical mineral supply chain, and we look forward to our continuing collaboration as the project moves forward,” said Richard Sadowsky, Interim CEO, RecycLiCo.
Alaska Energy Metals President & CEO Gregory Beischer commented, “We were invited to join Minerals for National Automotive Competitiveness (MINAC), a collaboration amongst upstream raw material suppliers, mid-stream metal refiners, and end users in America’s automotive industry, with the goal of creating all-American supply chains. AEMC was honored to enter this collaborative group which includes RecycLiCo, Lucid and others. It is great to see tangible collaboration in action, and we are excited to see how the RecycLiCo process works on recovering the various metals from concentrates we have produced from the Eureka deposit.”
QUALIFIED PERSON
Mr. Gregory Beischer, AEMC Company President & CEO, is the Qualified Person as defined by National Instrument 43-101 Standards of Disclosure for Mineral Projects. He has prepared and is responsible for the scientific and technical information contained in this press release.
RecycLiCo Battery Materials Inc. is a critical minerals refining company specializing in the use of advanced hydrometallurgical technologies for processing mined ore and the upcycling of lithium-ion battery materials. RecycLiCo’s processes efficiently recover battery-ready lithium, cobalt, nickel, and manganese from end-of-life batteries and manufacturing scrap, supporting energy storage as well as broader industrial applications. RecycLiCo’s business focus aligns with the global demand for future-ready, responsible supply chains and the growing movement to strengthen domestic sourcing of critical materials.
About Alaska Energy Metals
Alaska Energy Metals Corporation (AEMC) is an Alaska-based corporation with offices in Anchorage and Vancouver working to sustainably deliver the critical materials needed for national security and a bright energy future, while generating superior returns for shareholders.
AEMC is focused on delineating and developing the large-scale, bulk-tonnage, polymetallic Nikolai Project Eureka deposit containing nickel, copper, cobalt, chromium, iron, platinum, palladium, and gold. Located in Interior Alaska near existing transportation and power infrastructure, its flagship project, Nikolai, is well-situated to become a significant domestic source of strategic metals for North America. AEMC also holds a secondary project in western Quebec; the Angliers – Belleterre project. Today, material sourcing demands excellence in environmental performance, technological innovation, carbon mitigation and the responsible management of human and financial capital. AEMC works every day to earn and maintain the respect and confidence of the public and believes that ESG performance is measured by action and led from the top.
| For more information, please contact: | |
| Paola Ashton | Gregory A. Beischer |
| PRA Communications | AEMC President & CEO |
| Telephone: 604-681-1407 | 907-677-7479 |
| Email: pashton@pracommunications.com | info@alaskaenergymetals.com |
FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)
1. KEY INFORMATION
| (a) Full name of discloser: | Man Group PLC |
| (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. |
|
| (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree |
Gamma Communications plc |
| (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: | |
| (e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure |
26/10/2026 |
| (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? | NO |
2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.
(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
| Class of relevant security: | 0.25p ordinary | |||
| Interests | Short positions | |||
| Number | % | Number | % | |
| (1) Relevant securities owned and/or controlled: | 761,936 | 0.85 | ||
| (2) Cash-settled derivatives: | 456,789 | 0.51 | ||
| (3) Stock-settled derivatives (including options) and agreements to purchase/sell: | ||||
| TOTAL: | 1,218,725 | 1.36 | ||
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
(b) Rights to subscribe for new securities (including directors’ and other employee options)
| Class of relevant security in relation to which subscription right exists: | |
| Details, including nature of the rights concerned and relevant percentages: |
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
| Class of relevant security | Purchase/sale | Number of securities | Price per unit |
(b) Cash-settled derivative transactions
| Class of relevant security | Product description e.g. CFD |
Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position |
Number of reference securities | Price per unit |
| 0.25p ordinary | Equity swap | Reducing a long position | 14,832 | 10.9059 GBP |
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
| Class of relevant security | Product description e.g. call option | Writing, purchasing, selling, varying etc. | Number of securities to which option relates | Exercise price per unit | Type e.g. American, European etc. |
Expiry date | Option money paid/ received per unit |
(ii) Exercise
| Class of relevant security | Product description e.g. call option |
Exercising/ exercised against | Number of securities | Exercise price per unit |
(d) Other dealings (including subscribing for new securities)
| Class of relevant security | Nature of dealing e.g. subscription, conversion |
Details | Price per unit (if applicable) |
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
| Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: |
| None |
(b) Agreements, arrangements or understandings relating to options or derivatives
| Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: |
| None |
(c) Attachments
| Is a Supplemental Form 8 (Open Positions) attached? | NO |
| Date of disclosure: | 27/10/2026 |
| Contact name: | Molly Childs |
| Telephone number: | +44 20 7144 3714 |
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.
The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.
#FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)
1. KEY INFORMATION
| (a) Full name of discloser: | Man Group PLC |
| (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. |
|
| (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree |
Rotork Plc |
| (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: | |
| (e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure |
26/10/2026 |
| (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? | NO |
2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.
(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
| Class of relevant security: | 0.5p ordinary | ||||
| Interests | Short positions | ||||
| Number | % | Number | % | ||
| (1) Relevant securities owned and/or controlled: | |||||
| (2) Cash-settled derivatives: | 15,516,247 | 1.89 | 11,213 | 0.00 | |
| (3) Stock-settled derivatives (including options) and agreements to purchase/sell: | |||||
| TOTAL: | 15,516,247 | 1.89 | 11,213 | 0.00 | |
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
(b) Rights to subscribe for new securities (including directors’ and other employee options)
| Class of relevant security in relation to which subscription right exists: | |
| Details, including nature of the rights concerned and relevant percentages: |
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
| Class of relevant security | Purchase/sale | Number of securities | Price per unit |
| 0.5p ordinary | Sale | 83,979 | 4.9228 GBP |
(b) Cash-settled derivative transactions
| Class of relevant security | Product description e.g. CFD |
Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position |
Number of reference securities | Price per unit |
| 0.5p ordinary | Equity Swap | Reducing a long position | 4,360 | 4.9228 GBP |
| 0.5p ordinary | Equity Swap | Reducing a long position | 1,508 | 4.9238 GBP |
| 0.5p ordinary | Equity Swap | Reducing a long position | 1,503 | 4.9228 GBP |
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
| Class of relevant security | Product description e.g. call option | Writing, purchasing, selling, varying etc. | Number of securities to which option relates | Exercise price per unit | Type e.g. American, European etc. |
Expiry date | Option money paid/ received per unit |
(ii) Exercise
| Class of relevant security | Product description e.g. call option |
Exercising/ exercised against | Number of securities | Exercise price per unit |
(d) Other dealings (including subscribing for new securities)
| Class of relevant security | Nature of dealing e.g. subscription, conversion |
Details | Price per unit (if applicable) |
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
| Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: |
| None |
(b) Agreements, arrangements or understandings relating to options or derivatives
| Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: |
| None |
(c) Attachments
| Is a Supplemental Form 8 (Open Positions) attached? | NO |
| Date of disclosure: | 27/10/2026 |
| Contact name: | Molly Childs |
| Telephone number: | +44 20 7144 3714 |
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.
The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.
FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)
1. KEY INFORMATION
| (a) Full name of discloser: | Man Group PLC |
| (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. |
|
| (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree |
Vesuvius plc |
| (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: | |
| (e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure |
26/10/2026 |
| (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? | YES Offeror: RHI Magnestia N.V. |
2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.
(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
| Class of relevant security: | 10p ordinary | |||
| Interests | Short positions | |||
| Number | % | Number | % | |
| (1) Relevant securities owned and/or controlled: | 13,143,478 | 5.29 | ||
| (2) Cash-settled derivatives: | 865,043 | 0.34 | 499,224 | 0.20 |
| (3) Stock-settled derivatives (including options) and agreements to purchase/sell: | ||||
| TOTAL: | 14,008,521 | 5.64 | 499,224 | 0.20 |
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
(b) Rights to subscribe for new securities (including directors’ and other employee options)
| Class of relevant security in relation to which subscription right exists: | |
| Details, including nature of the rights concerned and relevant percentages: |
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
| Class of relevant security | Purchase/sale | Number of securities | Price per unit |
| 10p ordinary | Sale | 58,519 | 4.5407 GBP |
(b) Cash-settled derivative transactions
| Class of relevant security | Product description e.g. CFD |
Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position |
Number of reference securities | Price per unit |
| 10p ordinary | Equity Swap | Reducing a long position | 4,074 | 4.5407 GBP |
| 10p ordinary | Equity Swap | Reducing a long position | 10,856 | 4.5407 GBP |
| 10p ordinary | Equity Swap | Reducing a long position | 161 | 4.5407 GBP |
| 10p ordinary | Equity Swap | Reducing a long position | 26,709 | 4.5407 GBP |
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
| Class of relevant security | Product description e.g. call option | Writing, purchasing, selling, varying etc. | Number of securities to which option relates | Exercise price per unit | Type e.g. American, European etc. |
Expiry date | Option money paid/ received per unit |
(ii) Exercise
| Class of relevant security | Product description e.g. call option |
Exercising/ exercised against | Number of securities | Exercise price per unit |
(d) Other dealings (including subscribing for new securities)
| Class of relevant security | Nature of dealing e.g. subscription, conversion |
Details | Price per unit (if applicable) |
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
| Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: |
| None |
(b) Agreements, arrangements or understandings relating to options or derivatives
| Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: |
| None |
(c) Attachments
| Is a Supplemental Form 8 (Open Positions) attached? | NO |
| Date of disclosure: | 27/10/2026 |
| Contact name: | Molly Childs |
| Telephone number: | +44 20 7144 3714 |
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.
The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.
Global regulatory clearances in the U.S. and Australia support initiation of a Phase 1b/2a study in relapsing and refractory ITP and wAIHA
Study expands immunology portfolio into autoimmune cytopenias, evaluating a short-duration subcutaneous regimen designed to deplete antibody-producing plasma cells
CAMBRIDGE, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) — Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that the U.S. Food and Drug Administration and Australian Therapeutic Goods Administration have granted clearance to initiate its global Phase 1b/2a clinical trial in adults with relapsing and refractory immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA). The open-label, multicenter study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary clinical activity of subcutaneously administered velinotamig, a BCMAxCD3 T cell engager.
ITP and wAIHA are serious, potentially life-threatening autoimmune blood disorders in which pathogenic autoantibodies contribute to the destruction of platelets and red blood cells, respectively. Patients with ITP and wAIHA often experience significant disease burden, including debilitating fatigue and reduced quality of life, as well as severe disease manifestations such as bleeding in ITP and anemia in wAIHA. Despite available therapies, many patients experience persistent or relapsing disease, remain dependent on chronic treatment, or develop substantial adverse events from current therapies, underscoring the need for approaches that can deliver sustained disease control.
“Our autoimmune portfolio is built around complementary T cell engagers targeting CD19 and BCMA, a strategic approach designed to address distinct immune cell populations that drive disease across a spectrum of autoimmune conditions,” said Jeffrey Jones, MD, MBA, Chief Medical Officer, Cullinan Therapeutics. “ITP and wAIHA are compelling settings for which targeting antibody-producing plasma cells with a defined course of velinotamig may deliver durable clinical benefit. Emerging clinical data with BCMA-directed therapies have provided proof of concept for this mechanism in autoimmune cytopenias, including in some patients whose disease persisted despite prior treatment with CAR T therapy.”
Clinical data evaluating velinotamig in autoimmune diseases will be presented by Genrix Bio at the American College of Rheumatology Convergence 2026 meeting on November 8, 2026. Updated results from an ongoing Phase 1b/2a study in refractory systemic lupus erythematosus are expected to further inform the role of BCMA-directed plasma cell depletion across autoimmune diseases.
About the Study
The Phase 1b/2a study of velinotamig is an open-label, multicenter study evaluating velinotamig in adults with relapsing and refractory ITP or wAIHA (NCT07738822). The study consists of two parts and will evaluate a defined course of four subcutaneous doses. Part A is the Phase 1b multiple-ascending dose portion and Part B is the Phase 2a dose-expansion portion and will further evaluate the selected dose regimen or regimens in separate ITP and wAIHA expansion groups. The study’s primary objectives are to evaluate safety, tolerability, and effect on disease activity.
About Velinotamig (CLN-803, GR1803)
Velinotamig is a BCMAxCD3 T cell engager designed to redirect cytotoxic T cells to target BCMA-expressing cells including pathogenic, autoantibody-producing plasma cells. Velinotamig is engineered with high-affinity binding to BCMA and lower affinity binding to CD3, with the goal of enhancing target cell depletion while minimizing non-specific T cell activation and associated cytokine-related toxicity. By targeting BCMA-expressing cells, velinotamig has the potential to address autoimmune diseases driven by pathogenic autoantibodies.
Cullinan holds a global (ex-Greater China), all indication, exclusive license to velinotamig from Genrix Bio. Genrix Bio is currently evaluating velinotamig in a Phase 1b/2a clinical trial in patients with refractory systemic lupus erythematosus (SLE) in China, with additional autoimmune indications under consideration. Cullinan Therapeutics has initiated a global, basket, open-label, multicenter study of velinotamig in autoimmune cytopenias, including immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA).
About Immune Thrombocytopenia (ITP)
Immune thrombocytopenia (ITP) is a heterogeneous autoimmune disease characterized by increased platelet destruction and impaired platelet production.1 Platelets play a critical role in blood clotting, and reduced platelet levels can lead to bruising, bleeding, debilitating fatigue, and impaired health-related quality of life.1,2 In severe cases, bleeding may be life-threatening.1 ITP may present as an acute, self-limited condition or follow a chronic and relapsing course, particularly in adults.1 In the U.S., the prevalence of chronic primary ITP among adults has been estimated at approximately 62,000 adults.3 Although currently available therapies can help manage platelet counts and reduce bleeding risk, many patients continue to experience relapses and the burden of ongoing disease management.1,2
About Warm Autoimmune Hemolytic Anemia (wAIHA)
Warm autoimmune hemolytic anemia (wAIHA) is a rare autoimmune disease in which warm-reactive autoantibodies cause the premature destruction of red blood cells, resulting in anemia.4 People living with wAIHA may experience debilitating fatigue, shortness of breath, jaundice, and other complications of anemia. The disease can be serious and potentially life-threatening.4 The prevalence of wAIHA among adults in the U.S. is estimated at approximately 33,300 adults.5,6 Achieving sustained disease control can remain challenging, particularly for patients with relapsing or refractory wAIHA, underscoring the need for additional treatment options.7
About Cullinan Therapeutics
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, disease-modifying T cell engagers for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients. Learn more about Cullinan at https://cullinantherapeutics.com/, and follow Cullinan on LinkedIn and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding the Company’s beliefs and expectations regarding: our clinical development plan and timeline for velinotamig, the clinical and therapeutic potential of velinotamig, the study design of our clinical trial for velinotamig, and other statements that are not historical facts. The words “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “plan,” “potential,” “project,” “pursue,” “will,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: uncertainty regarding the timing and results of regulatory submissions; the risk that any INDs, NDAs or other global regulatory submissions we may file with the FDA or other global regulatory agencies are not cleared or approved on our expected timelines, or at all; the success of our clinical trials and preclinical studies; the risks related to our ability to protect and maintain our intellectual property position; the risks related to manufacturing, supply, and distribution of our product candidates; the risk that any one or more of our product candidates, including those that are co-developed, will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies; the effect of changes in global economic conditions, including uncertainties related to international trade policies, tariffs and supply chain dynamics on our business and operations; and the success of any collaboration, partnership, license or similar agreements. These and other important risks and uncertainties discussed in our filings with the Securities and Exchange Commission, including under the caption “Risk Factors” in our most recent Annual Report on Form 10-K and subsequent filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except to the extent required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Moreover, except as required by law, neither the Company nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made.
Contacts
Investors
Nick Smith
+1 401.241.3516
nsmith@cullinantx.com
Media
Rose Weldon
+1 215.801.7644
rweldon@cullinantx.com
References
- Cooper, N. et al. (2019). Immune Thrombocytopenia. New England Journal of Medicine; 381:945-955. https://doi.org/10.1056/NEJMcp1810479
- Cooper, N., et al. (2025). Patient survey in immune thrombocytopenia (ITP): Identifying unmet needs related to treatment and disease control in patients living in the United States. British Journal of Haematology, 207(3), 1038-1046. https://doi.org/10.1111/bjh.20257
- Feudjo-Tepie, M. A., et al. (2008). Prevalence of diagnosed chronic immune thrombocytopenic purpura in the US: analysis of a large US claim database: a rebuttal. Journal of Thrombosis and Haemostasis; 6:711-712. https://doi.org/10.1111/j.1538-7836.2008.02911.x
- Brodsky, R. A. (2019). Warm Autoimmune Hemolytic Anemia. New England Journal of Medicine, 381, 647-654. https://doi.org/10.1056/NEJMcp1900554
- Krumme, A. et al. (2025). Prevalence and demographics of autoimmune hemolytic anemia in the United States. Blood, 146(Supplement 1):6239. https://doi.org/10.1182/blood-2025-6239
- Theodosia A. (2016) Warm antibody autoimmune hemolytic anemia. Hematology Am Soc Hematol Educ Program 2016 (1): 690–697. https://doi.org/10.1182/asheducation-2016.1.690
- Barcellini, W., & Fattizzo, B. (2024). Autoimmune Hemolytic Anemias: Challenges in Diagnosis and Therapy. Transfusion Medicine and Hemotherapy, 51, 321-331. https://doi.org/10.1159/000540475
